ANGIODYNAMICS Second Quarter 2022 Earnings PresentationJanuary 6, 2022 1

2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “projects,” “believes,” “seeks,” “estimates,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation and labor shortages), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2021. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue, and is similarly approved for commercialization in Canada, the European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.Notice Regarding Non-GAAP Financial MeasuresManagement uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics’ business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported adjusted EBITDA (income before interest, taxes, depreciation and amortization and stock-based compensation); adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics’ performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics’ underlying business. Management encourages investors to review AngioDynamics’ financial results prepared in accordance with GAAP to understand AngioDynamics’ performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics’ financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

Corporate Developments – Q2 and YTD Highlights 3 Continued focused investment in our 3 key Med Tech platforms: Auryon, Thrombectomy & NanoKnife Revised FY2021 Guidance 3 Updated FY22 Guidance $0.00 - $0.05 ~55% Commenced LMR of the AlphaVac Mechanical Thrombectomy device in SeptemberFull Market Launch commenced in December Revenue(unchanged) Adjusted EPSPrevious Guidance Updated Guidance Gross MarginPrevious Guidance Updated Guidance $310 - $315 million COVID-19 related headwinds persist Gross margin impacted by labor shortages, inflation and freightProcedural volume pressures Overall Q2 revenue growth of 7.6%Med Tech up 36.4%; Med Device up 0.8%$6.3 million in Auryon sales 29% YOY growth in Mechanical Thrombectomy9% YOY growth in NanoKnife disposables ($0.02) - $0.02 52% - 54% Overall YTD revenue growth of 8.6%Med Tech up 50.0%; Med Device 0.1% (excluding NHS, up 4.7%)$12.2 million in Auryon sales 21% YOY growth in Mechanical Thrombectomy20% YOY growth in NanoKnife disposables

Second Quarter and YTD Highlights Q2 FY2022 Q2 FY2021 Change YTD FY2022 YTD FY2021 Change Revenue $78,280 $72,770 7.6% $155,251 $142,986 8.6% Gross Margin 51.8% 55.2% (340 bps) 52.0% 53.1% (110 bps) Net Loss ($8,351) ($4,268) ($4,083) ($15,323) ($8,536) ($6,787) GAAP EPS ($0.21) ($0.11) ($0.10) ($0.39) ($0.22) ($0.17) Adjusted EPS ($0.02) $0.01 ($0.03) ($0.04) $0.03 ($0.07) Adjusted EBITDA $4,421 $5,158 ($737) $7,992 $9,625 ($1,633) Financial Performance$ in thousands (except per share data) 4

Second Quarter and YTD Highlights 5 Med Device Med Tech $10.5 $17.6 $59.7 $59.4 36.4% growth 0.8% growth Q2 Revenue Growth Q2 FY21 Q2 FY22 YTD Revenue Contribution Med Device Med Tech YTD FY21 YTD FY22 50.0% growth 0.1% growth Q2 Revenue Contribution YTD Revenue Growth

Second Quarter Highlights – Sales Growth Over Prior Periods Endovascular Therapies Q2 FY2022 YTD FY2022 Auryon 201% 285% Mechanical Thrombectomy* 29% 21% Thrombolytics (12%) (10%) Core Peripheral 5% 9% Venous Insufficiency (9%) (1%) Vascular Access Q2 FY2022 YTD FY2022 Midlines (5%) (25%) C3 (2%) 27% PICCs 12% (8%) Ports 9% 15% Dialysis 0% (4%) Oncology Q2 FY2022 YTD FY2022 NanoKnife® Capital (54%) 2% NanoKnife® Disposables 9% 20% Solero® Microwave (3%) (6%) BioSentry 4% 12% Alatus and IsoLoc Balloons (7%) (1%) RadioFrequency Ablation (29%) (11%) 6 Med Tech Q2 FY2022 YTD FY2022 Auryon* 201% 285% Thrombectomy** 21% 15% NanoKnife® Disposables 9% 20% NanoKnife® Capital (54%) 2% Med Device Q2 FY2022 YTD FY2022 Solero® Microwave (3%) (6%) BioSentry 4% 12% Core Peripheral 5% 9% Venous Insufficiency (9%) (1%) Alatus and IsoLoc Balloons (7%) (1%) RadioFrequency Ablation (29%) (11%) Midlines (5%) (25%) C3 (2%) 27% PICCs 12% (8%) Ports 9% 15% Dialysis 0% (4%) * The Auryon product was launched in Q2 of fiscal year 2021. ** Thrombectomy is comprised of AngioVac, AlphaVac and Thrombolytics. * Mechanical thrombectomy is comprised of AngioVac and AlphaVac.

Second Quarter and YTD FY2022 Results (unaudited) $ in thousands (except per share data) Q2 FY2022 Q2 FY2021 Change YTD FY2022 YTD FY2021 Change Revenue $78,280 $72,770 7.6% $155,251 $142,986 8.6% Med Tech Med Device $18,886$59,394 $13,849$58,921 36.4%0.8% $36,504$118,747 $24,335$118,651 50.0%0.1% Endovascular Therapies Vascular Access Oncology $39,660$25,070$13,550 $33,900$23,930$14,940 17.0%4.8%(9.3%) $77,718$50,026$27,507 $63,757$52,035$27,194 21.9%(3.9%)1.2% United States International $65,350$12,930 $60,684$12,086 7.7%7.0% $129,814$25,437 $114,792$28,194 13.1%(9.8%) Net LossNon-GAAP Adjusted Net Income (Loss) ($8,351)($856) ($4,268)$564 ($4,083)($1,420) ($15,323)($1,743) ($8,536)$1,181 ($6,787)($2,924) GAAP EPSNon-GAAP Adjusted EPS ($0.21)($0.02) ($0.11)$0.01 ($0.10)($0.03) ($0.39)($0.04) ($0.22)$0.03 ($0.17)($0.07) Gross Margin 51.8% 55.2% (340 bps) 52.0% 53.1% (110 bps) Adjusted EBITDA $4,421 $5,158 ($737) $7,992 $9,625 ($1,633) $ in thousands Q2 FY2022 Q4 FY2021 Change Cash $34,291 $48,161 ($13,870) Debt $25,000 $20,000 $5,000 Net Cash $9,291 $28,161 ($18,870) 7

GAAP to Non-GAAP Reconciliation 8

Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS Reconciliation of Net Loss to Adjusted EBITDA Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items. Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended November 30, 2021 and November 30, 2020.Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss. 9 Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items. (in thousands, except per share data) (in thousands)